Impedimed Ltd has released a press release.
FDA Clearance for SOZO Heart Failure Index
Filed with ASX ·
Watch Impedimed's latest callImpedimed (ASX:IPD) Q1 2027 Earnings Call · Replay · Oct 29Read the transcript of Impedimed (ASX:IPD) Q1 2027 Earnings Call6ix hasn’t read this filing yet.
Story so far
Earlier from Impedimed
- SOZO Clinical Utility in Heart Failure Published
- Option Exercise and Preliminary Q3 FY21 Cashflow Results
- ImpediMed Achieves Milestone 200,000 SOZO Patient Tests
- Appendix 4D - Half-Year Results Ended 31 December 2020
- American College of Cardiology Accepts SOZO HF Abstract
Later from Impedimed
- Appendix 4C - Quarter ended 31 March 2021
- ACC Abstract Demonstrates Potential of SOZO in Heart Failure
- Official Release of SOZO Version 4.0 Software
- FDA Grants Breakthrough Device Designation for Renal Failure
- Receipt of $1.8 Million R&D Tax Incentive Refund
Follow Impedimed into a list and get an email when it puts out news.
Follow Impedimed